DK0862567T3 - 5-azabicyclo[3.1.0]hexylalkyl-2-piperidoner og-glutarimider som neurokininreceptorantagonister - Google Patents

5-azabicyclo[3.1.0]hexylalkyl-2-piperidoner og-glutarimider som neurokininreceptorantagonister

Info

Publication number
DK0862567T3
DK0862567T3 DK96938206T DK96938206T DK0862567T3 DK 0862567 T3 DK0862567 T3 DK 0862567T3 DK 96938206 T DK96938206 T DK 96938206T DK 96938206 T DK96938206 T DK 96938206T DK 0862567 T3 DK0862567 T3 DK 0862567T3
Authority
DK
Denmark
Prior art keywords
alkyl
aryl
pct
c6alkyl
optionally substituted
Prior art date
Application number
DK96938206T
Other languages
English (en)
Inventor
Alexander Roderick Mackenzie
Allan Patrick Marchington
Donald Stuart Middleton
Sandra Dora Meadows
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Application granted granted Critical
Publication of DK0862567T3 publication Critical patent/DK0862567T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK96938206T 1995-11-25 1996-11-11 5-azabicyclo[3.1.0]hexylalkyl-2-piperidoner og-glutarimider som neurokininreceptorantagonister DK0862567T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9524157.6A GB9524157D0 (en) 1995-11-25 1995-11-25 Therapeutic agents
PCT/EP1996/005000 WO1997019942A1 (en) 1995-11-25 1996-11-11 5-azabicyclo(3.1.0)hexylalkyl-2-piperidones and -glutarimides as neurokinin receptor antagonists

Publications (1)

Publication Number Publication Date
DK0862567T3 true DK0862567T3 (da) 2001-10-08

Family

ID=10784466

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96938206T DK0862567T3 (da) 1995-11-25 1996-11-11 5-azabicyclo[3.1.0]hexylalkyl-2-piperidoner og-glutarimider som neurokininreceptorantagonister

Country Status (13)

Country Link
US (1) US6034082A (da)
EP (1) EP0862567B1 (da)
JP (1) JP2978566B2 (da)
AT (1) ATE203747T1 (da)
CA (1) CA2230936C (da)
DE (1) DE69614270T2 (da)
DK (1) DK0862567T3 (da)
ES (1) ES2159764T3 (da)
GB (1) GB9524157D0 (da)
GR (1) GR3036688T3 (da)
MX (1) MX9804105A (da)
PT (1) PT862567E (da)
WO (1) WO1997019942A1 (da)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9812037D0 (en) * 1998-06-04 1998-07-29 Pfizer Ltd Piperidones
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
WO2001032625A1 (en) 1999-11-03 2001-05-10 Du Pont Pharmaceuticals Company Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
JP5132864B2 (ja) 2000-07-11 2013-01-30 アルバニー モレキュラー リサーチ， インコーポレイテッド ４−フェニル置換テトラヒドロイソキノリンおよびその使用方法
AU2003223010A1 (en) * 2003-04-10 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2005274927B2 (en) 2004-07-15 2011-11-03 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2699567A1 (en) 2011-04-21 2014-02-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
DK2925888T3 (da) 2012-11-28 2017-12-18 Merck Sharp & Dohme Sammensætninger og fremgangsmåder til behandling af cancer
EP2935263B1 (en) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
GEP20227402B (en) * 2017-09-07 2022-08-10 Valenta Intellekt Ltd Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
GB2606804B (en) 2019-07-17 2023-12-27 2692372 Ontario Inc Benzenesulfonamide derivatives and uses thereof
WO2021099842A1 (en) * 2019-11-22 2021-05-27 2692372 Ontario Inc. Pentafluorobenzenesulfonamide derivatives and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2676055B1 (fr) * 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
TW432061B (en) * 1994-08-09 2001-05-01 Pfizer Res & Dev Lactams

Also Published As

Publication number Publication date
GR3036688T3 (en) 2001-12-31
JP2978566B2 (ja) 1999-11-15
EP0862567B1 (en) 2001-08-01
MX9804105A (es) 1998-09-30
EP0862567A1 (en) 1998-09-09
CA2230936C (en) 2001-09-11
CA2230936A1 (en) 1997-06-05
ES2159764T3 (es) 2001-10-16
PT862567E (pt) 2001-11-30
WO1997019942A1 (en) 1997-06-05
US6034082A (en) 2000-03-07
ATE203747T1 (de) 2001-08-15
GB9524157D0 (en) 1996-01-24
JPH10512598A (ja) 1998-12-02
DE69614270D1 (de) 2001-09-06
DE69614270T2 (de) 2001-11-15

Similar Documents

Publication Publication Date Title
ATE203747T1 (de) 5-azabicyclo(3.1.0.)hexylalkyl-2-piperidone und - glutarimide als neurokinin receptor antagonisten.
NZ511739A (en) New esters derived from substituted phenyl-cyclohexyl compounds
NO20021399L (no) Kazolinderivater og deres anvendelse som farmasöyter
TR200400185T4 (tr) PDE 5 inhibitörleri olarak, 8-kuinolinkisantin ve 8-izokuinolinkisantin türevleri.
AU560579B2 (en) N-aromatic-n:-cycloalkylalkanoyl-piperazines
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists
NO20101069L (no) Anvendelse av visse NMDA-affinitetsantagonister som antidepressiva
PH12015501098A1 (en) Antituberculous composition comprising oxazole compounds
MY116280A (en) A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist
HRP20000508B1 (hr) Supstituirani 2-benzilamino-2-fenil-acetamidni spojevi
FI922341A0 (fi) Piperidin- och pyrrolidinderivat.
CA2195924A1 (en) 3-Aza and 3-Oxa-Piperidone Tachykinin Antagonists
DK1320526T3 (da) Farmaceutisk aktive benzsulfonamidderivater som inhibitorer af protein-junkinaser
ATE176232T1 (de) Verwendung dimethylbenzofuran und dimethylbenzopyran derivate als 5-ht3 antagoniste
DE60110233D1 (de) Neue n-(2-phenyl-3-aminopropyl)naphtamide
ES2193047T3 (es) (3,4 dihydro-2h-benzo(1,4) oxazinilmetil)(3-(1h-indol-3-il)-alquil)-aminas.
HRP20020347B1 (en) Phenyl-and pyridyl-tetrahydro-pyridines having tnf inhibiting activity
SE0100344D0 (sv) New Use
DK0667860T3 (da) Azaspiroalkan-derivater som terapeutiske midler